IO Interactive Welcomes Ulas Karademir as New Chief Technology Officer
15.5.2024 16:00:00 EEST | Business Wire | Press release
IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Ulas Karademir will be joining IOI as its new Chief Technology Officer, reporting to IOI’s CEO, Hakan Abrak. This strategic appointment to IOI’s leadership confirms the studio’s commitment to delivering groundbreaking experiences to its players. In his new role, Ulas will oversee IOI’s technical operations, the continuous development of Glacier, IOI’s proprietary in-house game engine, as well as working closely with the production team on the studio’s current projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240513208152/en/
Ulas Karademir © IO Interactive
Ulas is a familiar face at IO Interactive, having worked there for more than seven years between 2007 and 2014. With over 20 years of experience in engineering and leadership, Ulas held roles at Unity, including over 7 years as Vice President of Core Engineering, Graphics, Operations, and Productions, and most recently at RealityOS as General Manager and CPO.
"From the moment I stepped away from the studio, I felt deep down that I would find my way back, and now, that moment has arrived. I eagerly anticipate contributing to incredible titles such as Hitman, Glacier, Project 007 and Project Fantasy and the awesome management team Hakan put together. IOI has always been known for innovation, great gameplay, and immersive worlds, and I am determined to elevate our standards even further," shared Ulas Karademir.
“Ulas is a tremendous addition to our team, bringing with him invaluable experience, knowledge, and leadership. Since he left IOI, Ulas has had an incredible track record in the different companies he worked in, and we are very excited to welcome him once more. As IOI is growing and we are looking to bring amazing IPs to our players, Ulas will be at the forefront of our innovative endeavors,” said Hakan Abrak, CEO of IO Interactive.
Ulas Karademir’s arrival is the latest of IO Interactive's appointments among its leadership, with Veronique Lallier having joined as its Chief Development Officer last January and Olivier Perbet as its Chief Marketing Officer last year.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers
About IO INTERACTIVE
IO Interactive is an independent videogame developer and publisher with studios in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton. As the creative force behind some of the most talked-about multiplatform videogames in the last two decades, IOI is dedicated to creating unforgettable characters and experiences using their award-winning proprietary Glacier technology. IO Interactive will develop and publish the very first James Bond origin story with the working title Project 007 and is currently developing a new IP under the codename Project Fantasy. For more information, visit: https://ioi.dk.
© 2024 IO Interactive A/S. IO Interactive, IOI, HITMAN are registered trademarks of IO Interactive A/S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240513208152/en/
Contact information
Global Senior Communication Manager
Yann Roskell
press@ioi.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom